tocilizumab,nitedanib
roche,jw pharma,Boehringer Ingelheim
['tocilizumab', 'toci']
treatment of ssc-ild ---first regimen: mmf &gt; cyc ---tocilizumab: efficient in ssc-ild, but failed at primary end point (mrss) ---nitedanib (senscis study, nejm2019) ---rtx: stabilization in ild (desures study) similar with cyc (rct: recital trial)
#eular2023
★リウマチ専門医・指導医・総合内科専門医★現在は研究がメイン★ 発言は個人の責任で所属する施設に関係しません。